Immune correlates of protection against anthrax
暂无分享，去创建一个
Bacillus anthracis protective antigen (PA) has been produced from a recombinant B. subtilis and its efficacy, when combined with the Ribi adjuvant (MPL‐TDW‐CWS) or alhydrogel, has been compared with that of the licensed UK human vaccine, in guinea pigs challenged with aerosolized Ames strain spores. Recombinant PA combined with the Ribi adjuvant performed as well as PA from B. anthracis cultures in previous reports ( Ivins & Welkos 1986 ; Ivins et al. 1990 ; Turnbull et al. 1991 ; Jones et al. 1996 ; McBride et al. 1998 ) giving protection in 100% of animals exposed to the highest challenge dose of the Ames strain of B. anthracis that can be administered practically (retained lung doses of approximately 106 spores).
[1] L. Baillie,et al. Protective efficacy of a recombinant protective antigen against Bacillus anthracis challenge and assessment of immunological markers. , 1998, Vaccine.
[2] P. Turnbull,et al. Anthrax vaccines: past, present and future. , 1991, Vaccine.
[3] S. Welkos,et al. Cloning and expression of the Bacillus anthracis protective antigen gene in Bacillus subtilis , 1986, Infection and immunity.